Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus BRYHALI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus BRYHALI.
AMCINONIDE vs BRYHALI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
BRYHALI (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through the induction of phospholipase A2 inhibitory proteins (lipocortins), which inhibit the release of arachidonic acid and subsequent prostaglandin and leukotriene synthesis.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Apply a thin layer to affected areas once daily. For psoriasis, maximum weekly dose of 60 g. Do not exceed 100 g per week. For atopic dermatitis, do not exceed 60 g per week.
None Documented
None Documented
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Terminal elimination half-life is 1-4 hours in fast acetylators and 2-5 hours in slow acetylators (AUC significantly higher in slow acetylators). This influences dosing frequency; slow acetylators may require lower doses to avoid accumulation and toxicity.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Primarily hepatic metabolism followed by renal excretion of metabolites. Unchanged BRYHALI (isoniazid) is excreted renally: 50-70% as parent drug and metabolites (acetylisoniazid, isonicotinic acid) within 24 hours. Less than 5% excreted unchanged in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."